Try our beta test site
18 studies found for:    weill | Open Studies | "Intestinal Diseases"
Show Display Options
Rank Status Study
1 Recruiting Endoluminal and Needlescopic Assisted Repair of Rectal Prolapse
Condition: Rectal Prolapse
Intervention: Procedure: endoluminal rectal prolapse repair under sedation
2 Not yet recruiting Endoscopic Resection Multicenter Registry
Conditions: Gastrointestinal Neoplasms;   Gastrointestinal Disease;   Gastric Cancer;   Gastric Neoplasm;   Gastric Polyp;   Esophageal Neoplasms;   Duodenal Neoplasms;   Duodenal Polyp;   Stomach Neoplasm;   Stomach Polyp;   Neoplasms;   Colon Polyp;   Colon Neoplasm
Intervention: Procedure: Endoscopic Resection
3 Recruiting Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders
Conditions: Ampullary Cancer;   Duodenal Cancer;   Bile Duct Cancer;   Bile Duct Disorders;   Gallstones;   Obstructive Jaundice;   Pancreatic Disorders (Noncancerous);   Colorectal Cancer;   Esophageal Cancer;   Barrett's Esophagus;   Gastric Malignancies;   Pancreatic Cancer;   Pediatric Gastroenterology;   Cholangiocarcinoma;   Pancreatic Pseudocysts;   Acute and Chronic Pancreatitis;   Recurrent Pancreatitis;   Cholangitis;   Bile Leak;   Biliary Strictures;   Pancreatic Divisum;   Biliary and Pancreatic Stones;   Choledocholithiasis
Intervention: Procedure: Interventional Endoscopy
4 Recruiting 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
Conditions: Kidney Cancer;   Head and Neck Cancer;   Breast Cancer;   Non-small Cell Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Esophageal Cancer;   Gliomas
Intervention: Drug: 177Lu-J591
5 Not yet recruiting Imaging Biomarkers in Crohn's Associated Spondyloarthritis
Conditions: Crohn's Disease;   Spondyloarthritis
Intervention: Other: No intervention
6 Recruiting Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Condition: KRAS Mutant Metastatic Colorectal Cancer
Interventions: Biological: REOLYSIN®;   Drug: Irinotecan;   Drug: Leucovorin;   Drug: Fluorouracil (5-FU);   Drug: Bevacizumab
7 Recruiting Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
Condition: Crohn Disease
Intervention: Drug: etrolizumab
8 Recruiting A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: Etrolizumab 210 mg;   Drug: Etrolizumab 105 mg;   Drug: Placebo
9 Recruiting A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: GED-0301;   Other: Placebo
10 Recruiting Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: GED-0301;   Drug: Placebo
11 Recruiting A Study of LY3074828 in Participants With Moderate to Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: LY3074828;   Drug: Placebo
12 Recruiting A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors
Condition: Ulcerative Colitis
Interventions: Drug: Etrozulimab;   Drug: Placebo
13 Recruiting A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Condition: Colitis, Ulcerative
Interventions: Drug: Etrolizumab;   Drug: Placebo
14 Recruiting Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
Condition: Ulcerative Colitis
Intervention: Drug: Etrolizumab
15 Recruiting Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome
Condition: Lynch Syndrome
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Naproxen;   Other: Placebo
16 Recruiting A Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection
Conditions: Rectal Cancer;   Rectosigmoid Cancer
Interventions: Device: PINPOINT;   Device: SPY Elite
17 Recruiting PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Condition: Colorectal Cancer
Interventions: Drug: FOLFOX (chemotherapy);   Other: 5 FUCMT (chemoradiation);   Procedure: surgery;   Procedure: magnetic resonance imaging or endorectal ultrasound
18 Recruiting Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Conditions: Colorectal Cancer;   Gastric Adenocarcinoma;   Esophageal Cancer;   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Ovarian Epithelial Cancer;   Carcinoma Breast Stage IV;   Hormone-refractory Prostate Cancer;   Pancreatic Ductal Adenocarcinoma;   Head and Neck Cancers- Squamous Cell;   Renal Cell Cancer;   Urinary Bladder Neoplasms;   Cervical Cancer;   Endometrial Cancer;   Follicular Thyroid Cancer;   Glioblastoma Multiforme
Intervention: Drug: IMMU-132

Study has passed its completion date and status has not been verified in more than two years.